Trial intelligence / Profile preview

Clinical and biological effects of 5-azacitidine in symptomatic low-risk myelodysplastic syndromes

2007-003943-55Phase 2Active

Sponsor: ASST Spedali Civili di Brescia
Start: Nov 2007
Modality: Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
Countries: 1

Overview

Phase 2, open-label, single-arm trial of azacitidine in myelodysplastic syndrome (MDS), sponsored by ASST Spedali Civili di Brescia. Primary endpoints: Hematologic therapy response and Serious adverse events. Started Nov 2007; status: active.

Drugs

azacitidine

Conditions

myelodysplastic syndrome (MDS)

Beyond the preview

Go deeper on 2007-003943-55.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2007-003943-55.